Organon

Update in progress

OGN (NYSE)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - General

Organon & Co. develops women’s health therapies and medical devices for prescription use worldwide, including the United States, Europe, Canada, and beyond. Its women’s health portfolio covers contraception and fertility brands such as Nexplanon, NuvaRing, and daily pills, plus fertility drugs like Follistim and Elonva. It also offers biosimilars and medicines for cholesterol, hypertension, asthma, dermatology, bone health, and more. Based in Jersey City, NJ.

Company score

Sentiment: 0.39; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.02; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.51; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.11; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.13; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.26; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive